Introduction
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide and represents a growing public health burden in aging societies. Despite decades of research, current FDA-approved drugs provide only symptomatic relief and fail to halt or reverse disease progression. One of the major reasons for this limited success lies in the complex and multifactorial pathogenesis of AD, which involves amyloid-β (Aβ) deposition, tau hyperphosphorylation, cholinergic dysfunction, oxidative stress, neuroinflammation, and metabolic dysregulation. This complexity has driven a paradigm shift in drug discovery—from the traditional "one drug–one target" model toward multi-target and network-based therapeutic strategies. In this context, natural products have re-emerged as a particularly valuable source of anti-AD drug leads due to their structural diversity, biological relevance, and inherent polypharmacology.
Natural Products as a Rich Source of Anti-AD Bioactive Molecules
Natural products from plants, fungi, and marine organisms have historically contributed to many first-in-class drugs. In AD research, they offer unique advantages: multiple pharmacophores within a single molecule, evolutionary selection for bioactivity, and compatibility with complex biological systems. Recent studies have identified numerous natural compounds with potent anti-AD activities, including flavonoids, alkaloids, terpenoids, polyphenols, coumarins, and saponins. These compounds often exhibit favorable safety profiles and can simultaneously modulate multiple pathological processes, aligning well with the multifactorial nature of AD.
Single-Target Strategies from Anti-Alzheimer's Natural Products
Recent research has identified numerous natural compounds that precisely modulate specific AD-related targets:
Targeting Amyloid-β Pathology with Natural Compounds
The amyloid cascade hypothesis remains a central framework in AD research. Natural products have been shown to interfere with Aβ pathology at multiple levels, including Aβ generation, aggregation, clearance, and toxicity. Several flavonoids and polyphenols act as inhibitors of β-secretase (BACE1), the key enzyme responsible for initiating Aβ production. Others selectively modulate γ-secretase activity or directly bind Aβ peptides to prevent oligomerization and fibril formation. Certain polyphenolic compounds can even destabilize preformed Aβ fibrils, converting them into less toxic species.
Modulation of Tau Pathology through Enzyme and Aggregation Targets
Tau hyperphosphorylation and aggregation represent another pathological hallmark of AD. Natural products have demonstrated the ability to modulate tau pathology by targeting upstream kinases such as GSK-3β and CDK5, or by activating phosphatases like PP2A. In addition, certain chalcones, prenylated flavonoids, and cannabinoids can directly inhibit tau aggregation or promote the disassembly of tau fibrils. These effects are mediated by interactions with specific tau conformations or aggregation-prone domains.
Beyond Amyloid and Tau: Cholinergic, Oxidative, and Inflammatory Targets
AD pathology extends well beyond amyloid and tau. Natural products have been extensively reported to inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), thereby enhancing cholinergic neurotransmission. Alkaloids and diterpenoids are particularly prominent in this category. Other compounds target monoamine oxidases (MAO-A/B), reducing oxidative stress and neurotoxicity, while some saponins, sesquiterpenes, and phenolic acids modulate neuroinflammatory pathways by regulating receptors such as RAGE, estrogen receptors, and P-glycoprotein.
The Shift Toward Multi-Target Synergy
Given the failure of many single-target candidates in clinical trials, the field is shifting toward multi-target ligands. Natural products are inherently suited for this. Typical examples include:
- Ginsenosides (Rg1, Rd, Re): These compounds demonstrate remarkable polypharmacology, simultaneously promoting cholinergic signaling, inhibiting Aβ toxicity, and reducing tau phosphorylation through the GSK3β and CDK5 pathways.
- Curcumin and Rhizolutin: These molecules address both Aβ clearance and tau aggregation while providing anti-inflammatory benefits, showcasing the "one molecule, multiple hits" strategy.
While this polypharmacology offers clear therapeutic advantages, it also introduces significant challenges for drug development. Without a clear understanding of target engagement, it becomes difficult to determine which molecular interactions are responsible for efficacy, which contribute to synergy, and which may lead to off-target liabilities. From a translational perspective, insufficient target knowledge hampers rational lead optimization, biomarker development, and regulatory communication. In effect, many promising natural products remain trapped in a "phenotypic black box," where activity is observed but mechanism remains obscure.
Target Identification: The Missing Link Between Bioactivity and Drug Development
At this stage, the primary bottleneck in natural product–based AD drug discovery is no longer compound identification, but mechanistic deconvolution. Target identification serves as the critical bridge between phenotypic activity and rational drug development. Modern target identification aims to answer three fundamental questions:
(1) Which proteins or pathways does a bioactive compound directly interact with?
(2) How do these interactions translate into cellular and in vivo effects?
(3) Which targets are primary drivers of therapeutic efficacy?
Traditional hypothesis-driven approaches, such as testing compounds against a limited panel of known enzymes, are often insufficient for complex, multi-target natural products. Instead, unbiased, proteome-wide strategies are required to capture both expected and unexpected targets, enabling a systems-level understanding of mechanism of action.
Partner With Us
At our bioactive natural products target identification technology platforms, we focus on enabling the translation of natural product bioactivity into actionable molecular insight. Our platform integrates chemical biology, proteomics, and disease-relevant biology to systematically identify and validate targets of complex natural compounds.
Key capabilities include label-free target identification technologies such as TPP and DARTS, as well as affinity-based chemical proteomics for direct target fishing. These approaches allow proteome-wide target discovery without prior assumptions, making them particularly powerful for multi-target natural products. We also use AI-driven molecular docking and dynamics simulations to validate experimental findings.
In addition, we provide comprehensive pathway and network analysis, followed by orthogonal biochemical and cellular validation, to distinguish primary efficacy-driving targets from secondary effects.
